• 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>行业动态>全球药物合同制造行业研究报告

    江苏快3怎么看出要出龙: 全球药物合同制造行业研究报告

    okokok2009年5月18日 14:08 点击:1707

    时时彩网络平台 www.qlgr.net 全球药物合同制造行业研究报告——Pharmaceutical Contract Manufacturing
    这份报告分析了全球药物合同制造市场。 主要产品细分包含注射剂,,固体制剂(片剂和胶囊) ,液体剂型(糖浆和悬浮液)。 报告单独综合分析了美国,加拿大,日本,欧洲,亚太地区,以及世界其它地区市场,及全球84家公司。

    Countries covered: Global

    This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in Millions of US$. The Major product segments anaylzed are Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 84 companies including many key and niche players worldwide such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd., HAUPT Pharma AG, Jubilant Organosys Ltd., Kemwell Pvt. Ltd., NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd., and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources

    Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

    Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

    Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

    Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

    目录及图表

    I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
    Study Reliability and Reporting Limitations
    Disclaimers
    Data Interpretation & Reporting Level
    Quantitative Techniques & Analytics
    Product Definitions and Scope of Study
    II. EXECUTIVE SUMMARY
    1. Market Dynamics
    An Insight into the Rise of PCM
    Industry Potential
    2. Service Overview
    Introduction
    Injectables (injections, vials, and IV solutions)
    Solid Dosage Forms (SDFs) (Tablets and Capsules)
    Liquid Dosage Forms (LDFs) (Syrups and Suspensions)
    A Focus on Bio-Manufacturing
    3. Trends & Issues
    Outsourcing Emerges as a Strategic Priority for Pharmaceutical Companies
    Asia Dominates Regional Growth, North America Retains Position as Largest
    Market
    Virtual Pharma vs. Blockbuster Model
    Investment Risks in Pharmaceutical Contract Quality Assurance Risk
    Drug Development Risk
    Acquisition Risk
    Client Dependency Risk
    4. Recent Industry Activity
    Jubilant Acquires Draxis for US$ 253 Million
    JHP Acquires Assets of King Pharmaceuticals
    NextPharma Acquires Bioserv Corporation
    Dr. Reddy’s to Acquire Dowpharma’s Facilities
    PharmAthene to Acquire Avecia’s Biodefense Vaccine Operations
    Bioserv Enters into an Outsourcing Agreement with BioLife Solutions
    Eden Biodesign and Stealthyx Therapeutics Ink an Agreement
    NPIL Pharma to Expand HPS Sites in Scotland
    Dishman Pharma Installs New API Facilities
    Patheon Divests Niagara-Burlington Manufacturing Business to Pharmetics
    Jubilant Organosys Acquires Hollister-Stier Laboratories
    Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie
    Meda Acquires Recip
    Keata Pharma to Acquire Pfizer’s Production Facility in Canada
    STADA Acquires MAKIZ
    Nextpharma to Expand its Cytostatics Production Facility
    Haupt Pharma Establishes Production Facility in Malta
    Kemwell Pockets Pfizer’s Uppsala Sweden Based Manufacturing Plant
    Crucell and DSM Biologics Enter into a Licensing Agreement with UMN Pharma
    Lannett Inks a Multi-Product Contract Manufacturing Agreement with Wintac
    ATOZ Establishes Soft Gelatin Manufacturing Facility in Himachal Pradesh,
    India
    BASF Buys Orgamol SA
    Federa Completes Construction of Prefilled Syringes Facility
    BioProgress PLC Signs an Agreement with Custom Pharmaceuticals
    Safeguard Scientifics Acquires Laureate
    Patheon Buys MOVA Pharmaceutical
    Nichi-iko Strikes a Deal with Maruko Pharmaceutical
    DRAXIS Health Acquires Minority Stake in DRAXIS Pharma
    WPCC Receives FDA Acceptance
    Dechra Pharmaceuticals Acquires Anglian Pharma
    5. Focus on Select Global Players
    Althea Technologies (USA)
    Catalent Pharma Solutions (USA)
    Dishman Pharmaceuticals and Chemicals Ltd (India)
    HAUPT Pharma AG (Germany)
    Jubilant Organosys Ltd (India)
    Kemwell Pvt. Ltd (India)
    NextPharma (UK)
    Nipro Corp (Japan)
    Patheon, Inc. (Canada)
    Penn Pharmaceutical Services Ltd (UK)
    Royal DSM N.V. (Netherlands)
    6. Global Market Perspective
    Table 1: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 2: World Long-Term Projections for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 3: World 10-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific and Rest of World for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    Table 4: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 5: World Long-Term Projections for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - USA,Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 6: World 10-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific and Rest of World for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    Table 7: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 8: World Long-Term Projections for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 9: World 10-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific and Rest of World for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 11: World Long-Term Projections for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 12: World 10-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia- Pacific and Rest of World for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    III. MARKET
    1. The United States
    A. Market Analysis
    Current and Future Analysis
    Trends
    Pharma Companies Increasingly Outsource Manufacturing Activity
    Injectables Segment Witnesses Upward Growth Trend
    Competitive Landscape
    Strategic Corporate Developments
    Key Players
    Althea Technologies
    Catalent Pharma Solutions
    B. Market Analytics
    Table 13: US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 14: US Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 15: US 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    2. Canada
    A. Market Analysis
    Current and Future Analysis
    Strategic Developments
    Patheon, Inc. - A Key Canadian Player
    B. Market Analytics
    Table 16: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 17: Canadian Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 18: Canadian 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    3. Japan
    A. Market Analysis
    Current and Future Analysis
    Impact of Contract Manufacturing on Japanese Pharmaceutical Sector
    Nipro Corp - A Key Japanese Player
    B. Market Analytics
    Table 19: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 20: Japanese Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 21: Japanese 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    4. Europe
    A. Market Analysis
    Current and Future Analysis
    Trend
    Injectables Segment Offers Promising Potential
    Competitive Scenario
    Strategic Corporate Developments
    Key European Players
    HAUPT Pharma AG (Germany)
    NextPharma (UK)
    Penn Pharmaceutical Services Ltd (UK)
    Royal DSM N.V. (Netherlands)
    B. Market Analytics
    Table 22: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 23: European Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 24: European 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    5. Asia-Pacific
    A. Market Analysis
    Current and Future Analysis
    Trends
    Upbeat Market for Pharmaceutical Contract Manufacturing
    Competitive Scenario
    India
    Strategic Developments
    Select Players
    Dishman Pharmaceuticals and Chemicals Ltd (India)
    Jubilant Organosys Ltd (India)
    Kemwell Pvt. Ltd (India)
    B. Market Analytics
    Table 25: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 26: Asia-Pacific Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 27: Asia-Pacific 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    6. Rest of World
    Market Analysis
    Table 28: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
    Table 29: Rest of World Long-Term Projections for Pharmaceutical Contract Manufacturing by Product Segment - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    Table 30: Rest of World 10-Year Perspective for Pharmaceutical Contract Manufacturing by Product Segment - Percentage Breakdown of Dollar Sales for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
    IV. COMPETITIVE LANDSCAPE
    Total Companies Profiled: 84 (including Divisions/Subsidiaries - 87)
    Region/Country Players
    The United States29
    Canada6
    Japan 3
    Europe 33
    France 3
    Germany8
    The United Kingdom 9
    Italy 4
    Rest of Europe 9
    Asia-Pacific (Excluding Japan) 16
    (来源: okokok )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 甘肃福彩快3开奖号码 广西快乐双彩297期开奖 河南快3和值遗漏 网球王子之超神系统txt百度云 深圳捕鱼机遥控器 广西11选5历史号码 福彩中奖号码 nba篮彩看盘技巧 江苏快3开奖历史 体彩浙江6+1开奖号码 nba比分中文网 江西多乐彩有遗漏 3d往期开奖号码 二八杠教学揭秘视频 马會傅真图库